Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
14 May 2020GenericsRory O'Neill

Gilead agrees 127-country remdesivir licence with generic makers

Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Junshi licenses COVID-19 antibody tech from Lonza
14 July 2020   China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
Big Pharma
Gilead continues oncology expansion with Tizona deal
22 July 2020   Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Biotechnology
Junshi licenses COVID-19 antibody tech from Lonza
14 July 2020   China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
Big Pharma
Gilead continues oncology expansion with Tizona deal
22 July 2020   Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.

More on this story

Biotechnology
Junshi licenses COVID-19 antibody tech from Lonza
14 July 2020   China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
Big Pharma
Gilead continues oncology expansion with Tizona deal
22 July 2020   Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court